🇺🇸 FDA
Pipeline program

PIK3CA inhibitor

BCTOP-L-M05

Phase 2 small_molecule active

Quick answer

PIK3CA inhibitor for Breast Neoplasm is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Breast Neoplasm
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials